InvestSMART

Nyrada Inc (ASX: NYR) - Announcements

- Current share price for NYR : $0.415

ASX company news and announcements for Nyrada Inc (NYR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Nyrada Inc (NYR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Nyrada Inc (NYR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Nyrada Inc (NYR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$103 PROTECT-MI Phase IIa Clinical Trial Update No 2 6 Jul 2026 9:39AM $0.440 $0.415 fallen by 5.68%
$103 Notification of cessation of securities - NYR 30 Jun 2026 5:43PM $0.450 $0.415 fallen by 7.78%
$103 Cleansing Statement 30 Jun 2026 9:48AM $0.420 $0.415 fallen by 1.19%
$103 Application for quotation of securities - NYR 30 Jun 2026 9:46AM $0.420 $0.415 fallen by 1.19%
$103 Cleansing Statement 29 Jun 2026 6:11PM $0.420 $0.415 fallen by 1.19%
$103 Application for quotation of securities - NYR 29 Jun 2026 6:10PM $0.420 $0.415 fallen by 1.19%
$103 Cleansing Statement 16 Jun 2026 4:42PM $0.430 $0.415 fallen by 3.49%
$103 Application for quotation of securities - NYR 16 Jun 2026 4:39PM $0.430 $0.415 fallen by 3.49%
$103 Change of Director's Interest Notice - JB 16 Jun 2026 8:25AM $0.440 $0.415 fallen by 5.68%
$103 PROTECT-MI Phase IIa Clinical Trial Update 16 Jun 2026 8:24AM $0.440 $0.415 fallen by 5.68%
$103 Investor Presentation 4 Jun 2026 9:39AM $0.450 $0.415 fallen by 7.78%
$103 Nyrada Successfully Completes Cardioprotection Pilot Study 3 Jun 2026 1:39PM $0.450 $0.415 fallen by 7.78%
$103 Nyrada Receives A$2.455M R&D Tax Incentive Rebate 29 May 2026 9:45AM $0.515 $0.415 fallen by 19.42%
$103 Cleansing Statement 25 May 2026 5:19PM $0.540 $0.415 fallen by 23.15%
$103 Application for quotation of securities - NYR 25 May 2026 5:15PM $0.540 $0.415 fallen by 23.15%
$103 Upcoming Expiry of Unlisted Options 21 May 2026 12:56PM $0.585 $0.415 fallen by 29.06%
$103 Xolatryp Enhances Anthracycline Anti-Tumour Efficacy 20 May 2026 9:13AM $0.555 $0.415 fallen by 25.23%
$103 Trading Halt 19 May 2026 4:54PM $0.555 $0.415 fallen by 25.23%
$103 Pause in Trading 19 May 2026 3:37PM $0.560 $0.415 fallen by 25.89%
$103 Nyrada Receives Notice of Allowance for Xolatryp US Patent 19 May 2026 3:10PM $0.550 $0.415 fallen by 24.55%
$103 First Site Activated in Nyradas PROTECT-MI Phase IIa Trial 22 Apr 2026 12:30PM $0.600 $0.415 fallen by 30.83%
$103 Quarterly Activities Report and Appendix 4C 15 Apr 2026 8:45AM $0.580 $0.415 fallen by 28.45%
$103 Presentation - ASX SMIDCaps Conference 20 Mar 2026 8:37AM $0.505 $0.415 fallen by 17.82%
$103 Nyrada PROTECT-MI Phase IIa Trial To Commence 19 Mar 2026 9:55AM $0.535 $0.415 fallen by 22.43%
$103 Change of Director's Interest Notice - JM 9 Mar 2026 5:17PM $0.555 $0.415 fallen by 25.23%

1 - 25 of 490 results

Page 1 of 20

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.